|
1. |
adiponectin augmented the expression of A20, suppressor of cytokine signaling (SOCS) 3, B-cell CLL/lymphoma (BCL) 3, TNF receptor-associated factor (TRAF) 1, and TNFAIP3-interacting protein (TNIP) 3. |
|
|
2. |
Bcl-3 as an important modulator of cutaneous innate immune responses and its possible therapeutic role in atopic dermatitis (AD). |
|
|
3. |
Transcriptional profiling demonstrated that Bcl3 activates genes involved in diverse pathways including a subset involved in cellular energy metabolism known to be regulated by PGC-1alpha, ERRalpha, and a second nuclear receptor, PPARalpha. |
|
|
4. |
elevated lung levels of IL-10 may impair MTb-mediated alveolar macrophage apoptosis in HIV through a BCL-3-dependent mechanism |
|
|
5. |
activation of p52/Bcl-3 complexes in monocyte-derived macrophages (MDM) and p50/p65 heterodimers in fibroblasts in response to HCMV infection might explain the low-level growth of the virus in MDMs vs efficient growth in fibroblasts |
|
|
6. |
BCL3 is a common target gene for several growth-promoting cytokines in myeloma cells and high expression of BCL3 at the time of diagnosis is associated with poor prognosis of patients with multiple myeloma |
|
|
7. |
Buthionine sulfoximine activates a noncanonical, inhibitory NF-kappaB- and p65-independent NF-kappaB pathway via a multistep process leading to the up-regulation of Bcl-2 |
|
|
8. |
BCL2 or BCL3 are recurrent translocation partners of the IGH locus in cHL (classical Hodgkin lymphomas). |
|
|
9. |
Bcl-3 is rapidly induced following the expression of Epstein-Barr virus LMP1. |
|
|
10. |
Observational study of gene-disease association. (HuGE Navigator) |
|
|
11. |
Characterization of the mouse BCL3 ortholog and comparison to the human gene. |
|
|
12. |
demonstrated that HCCs almost universally overexpress Bcl-3 and preferentially express nuclear p52 and p50, with little evidence of p65 activation. |
|
|
13. |
induction of p50/p50/Bcl-3 complexes by latent membrane protein 1 (LMP1) C-terminal activating region 1 mediates LMP1-induced epidermal growth factor receptor upregulation |
|
|
14. |
BCL3 functions as a repressor of HTLV-1 LTR-mediated transcription through interactions with TORC3 |
|
|
15. |
study indicates that BCL3 translocations are not restricted to B-cell chronic lymphocytic leukemia but present in a heterogeneous group of B-cell malignancies |
|
|
16. |
High-level expression of BCL3 differentiates t(2;5)(p23;q35)-positive anaplastic large cell lymphoma from Hodgkin disease. |
|
|
17. |
Supported by IL-12 signals, Bcl-3 enhances survival and clonal expansion of transgenic OT-1 CD8 T cells. |
|
|
18. |
(p52)2/Bcl-3P ternary complex, which is specifically induced in CD30-stimulated anaplasstic larage cell lymphoma, can modulate expression of apoptosis-related genes regulated by NF-kappaB. |
|
|
19. |
Bcl-3 might participate in oncogenic pathways involving Lck |
|
|
20. |
overexpression of BCL3 increases apoptosis, whereas BCL3-specific siRNA does not affect the viability of INA-6 cells suggesting that BCL3 is not essential for the survival of these cells |
|
|
21. |
BCL3 is downregulated by p53 to repress cyclin D1 and has a role in regulation of cell cycle progression |
|
|
22. |
elevated Bcl-3 expression has an important function in classical Hodgkin lymphoma and peripheral T-cell non-Hodgkin lymphoma, in particular anaplastic large-cell lymphomas |
|
|
23. |
The relatively high frequency of BCL-3 expression in some non-Hodgkin and Hodgkin lymphoma types raises the possibility that BCL-3 is involved in the pathogenesis of these tumors, and may be a target of new therapies. |
|
|
24. |
HBx and NF-kappaB2/BCL3 mediated-cyclin D1 up-regulation might play an important role in the HBx-mediated HCC development and progression |